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A Ab bs st tr ra ac ct t
There is much debate in the literature about familial predispositions to breast and bowel cancers yet little evidence
is forthcoming to suggest that there are susceptibility genes that can account for such kindreds. Within the context
of known susceptibility genes the most controversial syndrome is hereditary non-polyposis colorectal cancer (HNPCC).
In HNPCC, breast cancers do occur yet their incidence overall is no different to that of the general population yet
when studied at the molecular level these tumours often display DNA microsatellite instability suggesting that they
do indeed belong to this genetic entity. In this review we examine the relationship between breast and bowel cancer
and suggest a possible explanation for the diverse points of view described in the literature. 
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I In nt tr ro od du uc ct ti io on n
Knowledge  about  the  genetics  of  inherited
predispositions to cancer has increased significantly
over  the  last  ten  years  yet  there  remain  many
unresolved issues. The identification of the genetic
basis of familial breast cancer and familial forms of
bowel cancer has resulted in the development of
much improved screening strategies for disease
prevention and has altered our awareness to disease
susceptibility. Notwithstanding, only a very small
proportion  of  bowel  and  breast  cancers  are
attributed to the inheritance of a predisposing gene
(approximately 2-7% and 5%, respectively) [1-5].
The discovery of many more cancer susceptibility
genes continues. Rapid technological advances are
aiding the cancer detection process, which will
ultimately lead to improved prevention of familial
bowel and breast cancer. 
Both bowel and breast cancers are prevalent
among the population and current investigations aim
to identify additional genes that contribute to these
genetic predispositions. Familial breast cancer and
familial bowel cancer outside of the context of known
genetic predispositions to disease (Peutz-Jeghers
syndrome (PJS), hereditary non-polyposis colorectal
cancer (HNPCC) or hereditary breast and/or ovarian
cancer or HBOC) indicate that there is an overlap
between the two predispositions within families. Based
on current information sourced from the literature, little
is known about the exact genetic relationship between
bowel and breast cancer risk. Before examining the
evidence for a breast/bowel cancer susceptibility gene
the relationship between the two malignancies should
be assessed within the context of known genetic
predispositions to disease. 
The main issues are sample populations, age of
onset,  differences  between  men  and  women,H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 26
Rodney J. Scott, Katie A. Ashton
microsatellite instability, cancer susceptibility genes and
the pathways that they encode. The purpose of this
review  is  to  illustrate  what  is  known  about  the
association between bowel and breast cancer and the
evidence for and against this notion. 
B Br re ea as st t   a an nd d   b bo ow we el l   c ca an nc ce er r   r ri is sk k   i in n   i in nh he er ri it te ed d
c ca an nc ce er r   s sy yn nd dr ro om me es s
The first investigations into HNPCC and breast
cancer were conducted by Watson and Lynch [6] in
1993, who showed that HNPCC patients have no
increased risk of developing breast cancer. Current
research however has identified the possibility that
individuals with HNPCC are predisposed to developing
breast cancer [7-9]. Studies examining the relationship
between bowel and breast cancer in HNPCC often
conflict  with  each  other  due  to  the  populations
investigated and the analysis performed. 
HNPCC is an autosomal dominant disease [4, 10,
11], the aetiology of which emerged from many
avenues that included linkage analysis, segregation
studies and molecular genetic analyses [12]. 
The genetic basis of HNPCC is, at least in part, due
to mutations in genes encoding proteins involved in
the DNA mismatch repair (MMR) pathway. The most
common mutations are found in the mutL homolog
1 (hMLH1) and mutS homolog 2 (hMSH2) MMR genes
[4, 10, 11, 13]. The available evidence suggests that
there is a direct association between MMR mutations
and HNPCC and that hMSH2 and hMLH1 account for
up to 60% of all families that adhere to the Amsterdam
criteria and about 30% if the Bethesda criteria are used
[4,  10-13].  The  mutS  homolog  6 (hMSH6)  and
postmeiotic segregation 2 (hPMS2) genes account for
only a small proportion of HNPCC families, probably
less than 5% [14]. Currently over 200 allelic variants
in hMSH2 and hMLH1 have been linked with HNPCC
[12].  Mutations  in  DNA  MMR  genes  result  in
a characteristic  tumour  signature  known  as
microsatellite instability (MSI), which can be used to
aid in the diagnosis of HNPCC. 
Like HNPCC, breast cancer development can occur
due to certain defective genes associated with the
maintenance of genomic integrity. Two intensely studied
genes are breast cancer gene 1 (BRCA1) and breast
cancer gene 2 (BRCA2). Both BRCA1 and BRCA2
appear to be linked to the recognition of DNA double
strand breaks and double strand break repair [15].
Genetic modeling studies, however, indicate that other
genes exist that predispose to breast cancer [16].
Mutations in BRCA1 account for more than 50% of
cases of breast cancer within a family of at least four
affecteds diagnosed under the age of 60. Carriers of
BRCA1 mutations have an 85% likelihood of developing
breast cancer by the age of 80. BRCA2 accounts for
approximately 30% of breast cancer families where there
are four or more cases also diagnosed under the age
of 60. Similar to BRCA1, carriers of BRCA2 mutations
have an 85% probability of developing breast cancer
by the age of 80 [3]. The disease spectrum observed in
BRCA1 families appears to be very restricted whereas
BRCA2  appears  to  be  associated  with  a more
pleiotropic disease phenotype (see this issue of the
journal for a review of BRCA1 and BRCA2 function). 
Within the context of HBOC families there appears
to be no relationship between breast and bowel cancer
although initially it was believed that mutations in
BRCA1 conferred an increased relative risk of bowel
cancer [17]. On re-examination with larger numbers
of families this relationship has since been shown not
to exist [18]. There is no evidence to suggest that
mutations in BRCA2 confer any increased risk of bowel
cancer. Together, it appears that HBOC families do not
have any increased risk of bowel cancer development
[18] which is in contrast to HNPCC families where the
epidemiological evidence remains inconclusive. 
B Br re ea as st t   c ca an nc ce er r   a an nd d   H HN NP PC CC C
Mutations  in  DNA  MMR  genes  appear  to  be
associated with an increased probability of epithelial
tumours, most notably bowel and endometrial cancers.
Additional to this are a variety of other less frequent
malignancies  that  have  been  noted  to  be
over-represented in HNPCC families and these include
cancers of the ureter, gall bladder, pancreas and
nasopharyngeal tumours. The notable exception is
breast cancer although it has been reported to be
present in HNPCC families. Since the identification of
DNA MMR genes and their association with HNPCC
there have been anecdotal reports of breast cancers
occurring  in  families  that  have  been  genetically
characterised. Small studies assessing the presence of
DNA microsatellite instability (MSI) revealed its presence
in breast tumours derived from patients who harboured
germline  MMR  gene  mutations  suggesting  by
association that breast tumours do occur as an entity
within the context of HNPCC [7-9]. When, however,
the incidence of breast tumours is examined in families
that adhere to either the Amsterdam or Bethesda
criteria no obvious statistically significant result can be
observed between them and the general population.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 27
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Scott et al (2001) subdivided HNPCC families into
three groups, those that harboured hMSH2 mutations,
hMLH1 mutations and mutation negative kindreds. The
standard incidence rate was determined and the
hMLH1 group displayed a small but significantly greater
incidence in breast cancer compared to the general
population. The result was unexpected but when
compared to the standard incidence rates of bowel
cancer and a number of other cancers it appeared to
be low. If all families were considered together the
incidence rate difference disappeared [10]. The results
of this study provided some evidence for breast cancer
to be considered part of the entity of HNPCC. 
Vasen et al (2001) provide some evidence that
breast tumours within HNPCC families present at an
earlier age than expected. They propose that MMR
gene mutation carriers are likely to have accelerated
tumour development which will be observed as early
onset breast cancer [19]. 
M Mi ic cr ro os sa at te el ll li it te e   i in ns st ta ab bi il li it ty y   ( (M MS SI I) )   a an nd d   H HN NP PC CC C
MSI studies have primarily focused on bowel cancer
rather than breast cancer and this potentially may
confound  the  interpretation  of  results.  The  DNA
microsatellite  markers  chosen  by  the  International
Collaborative Group for HNPCC was directed towards
the identification of MSI in colorectal cancers rather than
in other cancers [12, 19]. The microsatellite markers used
to assess MSI were chosen because of their relationship
to known genetic factors associated with bowel cancer
development and they include D5S534 (linked to the
APC gene), D2S123 (linked to hMSH2), D17S250 (linked
to TP53), Bat 26 (linked to a poly (A) tract in exon 5 of
MSH2) and Bat 25 (linked to a poly (A) tract in c kit).
When these markers are used to assess bowel tumours
derived from patients from HNPCC families approximately
90% will display MSI. In contrast, breast cancers derived
from HNPCC patients show a low rate of MSI and thereby
contributing to the difficulty in determining whether an
association between bowel and breast cancer exists [4,
13, 19-21]. There has been no systematic analysis of
genes associated with MMR in MSI negative patients even
though there are examples of mutations being found in
MSI negative tumours [12]. Liu et al (2000) for example,
showed MSI positive tumours in 16 out of possible 22
HNPCC patients, and they identified a DNA MMR
causative mutation in 1 of 37 MSI negative tumours [22].
Risinger et al (1996) demonstrated that MSI is much more
common in breast cancers from HNPCC families than in
their sporadic counterparts [9]. 
Risinger et al (1996), de Leeuw et al (2002), and
Boyd et al (1999) all demonstrate MSI in both breast
cancer tissue and bowel tumours harbouring hMLH1
mutations [7-9] and Vasen et al (2001) showed one
patient that exhibited MSI in a breast cancer tumour.
In contrast, Caluseriu et al (2001), and Muller et al
(2002) did not find MSI within the breast cancers they
investigated [4, 13]. Together, this information suggests
that MSI should not be the only technique used to
determine whether there is a bowel and breast cancer
association within the context of HNPCC. Mutational
analysis of the MMR genes should be performed.
Mitchell et al (2002) state that mutations that are
evident within MSI negative patients may show that
mutations in MMR genes do not always show MSI but
confer the mechanisms of tumorigenesis [12]. 
S Sa am mp pl le e   p po op pu ul la at ti io on ns s
The incidence rates of HNPCC vary globally and
they appear higher of developed countries. This
difference may be due to ethnicity and environmental
factors such as lifestyle and diet [12]. Scott et al (2001)
reported  in  an  Australian  population,  a higher
incidence of breast cancer in individuals with hMLH1
mutations and mutation negative patients compared
to patients with hMSH2 mutations [10]. Vasen et al
(2001) presented results from the Dutch population
showing no association between both cancers. In reply
to Vasen et al, Scott suggests that Dutch and Australian
populations differ in their HNPCC and breast cancer
incidences since hMLH1 mutations are more common
in the Australians. Scott concludes by agreeing that
breast cancer may present at an earlier age due to
MMR defective genes [19].
Vasen et al published data that indicates that there
is no association between bowel and breast cancer in
the Dutch population since only seven of 328 patients
exhibited mutations in hMLH1 and hMSH2 combined.
However, they state that the MMR pathway may lead
to more rapid tumour development thereby accounting
for the recognition of early onset breast cancer
development [19]. 
Other studies examining the relationship between
breast  and  bowel  cancer  have  only  used  small
populations of breast and bowel cancer patients. For
example, Borg et al (2000) discovered both a BRCA1
mutation and an hMLH1 mutation in the same individual.
They suggest from this finding that BRCA1 and hMLH1
mutations have a synergistic effect with respect to the
development of bowel and breast cancer [11]. To confirm
the existence of a relationship between breast and bowel
cancer in the context of HNPCC, much larger sample
populations must be studied to provide statistical rigour. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 28
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M Ma al le es s   v vs s. .   f fe em ma al le es s
Within the HNPCC population, males are more likely
to suffer from colorectal cancer than females. As age
increases within both sexes, HNPCC risk increases. Male
mutation carriers have almost twice the probability (80%)
of developing colorectal cancer than females (40%) by
the age of 70. This difference in penetrance between
the sexes is not understood, but may be due to hormonal
differences, the presence of a genetic modifier or an X-
linked  gene  that  confers  some  protection  against
colorectal disease [12]. Boyd et al. (1999) identified
malignancies within the breast and colon of a male
within HNPCC kindred. The male had an hMLH1
mutation, which segregated within the kindred. They
suggest that breast cancer can occur as an integral
tumour in HNPCC [7]. Cancer of the breast in males is
rare and accounts for approximately 0.5% of all breast
cancers in the US [7]. Further research may demonstrate
the slight differences in genetics of male and female
breast carcinomas in HNPCC families [11]. 
P Pr ro op po os si it ti io on n
We propose a possible explanation for the increased
risk of breast cancer seen within HNPCC individuals.
The relative age of onset of breast cancer within
individuals with both breast and bowel cancer is younger
at approximately 40 to 50 years of age compared to
the general population where disease peaks between
65 and 70 years of age. If germline changes in the MMR
genes accelerate disease development then it is to be
expected that disease initiation may occur at much
earlier stages and what is being observed in HNPCC is
merely a reflection of the population incidence of the
disease, which occurs approximately 20 years earlier
than  expected.  The  evidence  for  this  notion  is
circumstantial and is related to the clonal expansion of
the breast at puberty and during pregnancy [23]. If an
event occurs during puberty that results in a somatic
mutation in a gene that alters breast cancer risk on
a background of MMR deficiency then it is to be
expected that disease development will ensue. 
F Fu ut tu ur re e
The association of breast cancer with HNPCC
remains controversial but clues are beginning to emerge
that may solve this riddle once and for all. Recently, the
CHEK2 gene has been identified as a cofactor in breast
cancer risk. CHEK2 is a key mediator in DNA damage
response pathways. It is a G2 checkpoint kinase of the
cell cycle pathway and is involved with the TP53 and
BRCA1 pathways. CHEK2 is activated when there is
a problem with the cell cycle. This results in the
prevention of cellular entry into mitosis and thereby
prevents cell replication. In patients who harbour
germline mutations in CHEK2 the prevention of cell
replication does not occur when required, thereby
bypassing a critical checkpoint control mechanism [24]. 
Mutations in this gene have been associated with
an  increased  risk  of  breast  and  bowel  cancer
development and currently efforts are underway to
determine the precise relationship between CHEK2
and cancer risk in families that harbour both breast
and colorectal cancer patients [25]. 
A known polymorphism has been identified in
CHEK2 (1100delC), which has already been linked to
a hereditary breast and bowel cancer (HBBC) phenotype
[25]. This mutation causes dysfunction of the kinase
activity of the CHEK2 protein thereby losing a critical
aspect of cell checkpoint control. The frequency of the
known CHEK2 mutation is 1.1% in healthy individuals,
5.1% in breast cancer females with BRCA1 and BRCA2
mutations and 13.5% in male breast cancers. This data
suggests that CHEK2 contributes to cancer risk but is
not involved in disease initiation [24, 25]. 
C Co on nc cl lu us si io on n
The question ”Does familial breast and bowel
cancer exist?” cannot be unequivocally answered.
Individuals that harbour germline mutations in MMR
genes may be at increased risk of breast development
but it is likely not to be reflected by a simple increase
in disease incidence. More likely is the notion that
individuals harbouring germline MMR gene mutations
will have an accelerated disease process, which may
be influenced by an interaction with modifier genes. 
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